![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Tamoxifen (TAM) is a frequently used hormonal prodrug for patients with breast cancer that needs to be activated by cytochrome P450 2D6 (CYP2D6) into Zusammen-endoxifen (Z-END).
Objective: The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer.
Methods: A cross-sectional study was performed in 125 ambulatory patients with breast cancer consuming TAM at 20 mg/day for at least 4 months. The frequency distribution of CYP2D6*10 (c.100C>T) genotypes (C/C: wild type; C/T: heterozygous mutant; T/T: homozygous mutant) was detected using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), the results of which were subsequently confirmed by sequencing. The genotypes were categorized into plasma Z- END concentrations of <5.9 ng/mL and ≥5.9 ng/mL, which were measured using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
Results: Percentages of C/C, CT, and T/T genotypes were 22.4%, 29.6%, and 48.8%, respectively. Median (25-75%) Z-END concentrations in C/C, C/T, and T/T genotypes were 9.58 (0.7-6.0), 9.86 (0.7-26.6), and 3.76 (0.9-26.6) ng/mL, respectively. Statistical analysis showed a significant difference in median Z-END concentration between patients with T/T genotype and those with C/C or C/T genotypes (p<0.001). There was a significant association between CYP2D6*10 (c.100C>T) genotypes and attainment of plasma steady-state Z-END MTC (p<0.001).
Conclusion: There was a significant association between CYP2D6*10 (c.100C>T) and attainment of plasma steady-state Z-END MTC in Indonesian breast cancer patients receiving TAM at a dose of 20 mg/day.
Keywords: CYP2D6*10 (c.100C>T), breast cancer, tamoxifen, Z-endoxifen, steady state concentration, Indonesian population.
[http://dx.doi.org/10.6004/jnccn.2018.0012] [PMID: 29523670]
[http://dx.doi.org/10.1093/annonc/mdv221] [PMID: 25939896]
[http://dx.doi.org/10.1124/jpet.104.065607] [PMID: 15159443]
[http://dx.doi.org/10.1038/clpt.2011.32] [PMID: 21430657]
[http://dx.doi.org/10.1097/FTD.0000000000000257] [PMID: 26485084]
[http://dx.doi.org/10.1111/j.1365-2125.2011.03905.x] [PMID: 21480951]
[PMID: 24648760]
[http://dx.doi.org/10.1517/14622416.3.2.229] [PMID: 11972444]
[PMID: 22724048]
[http://dx.doi.org/10.2147/OTT.S149197] [PMID: 29180876]
[http://dx.doi.org/10.1186/s12885-015-1575-4] [PMID: 26232141]
[PMID: 25999696]
[PMID: 25870837]
[PMID: 27648149]
[http://dx.doi.org/10.1200/JCO.2009.25.7246] [PMID: 20124171]
[http://dx.doi.org/10.1186/2193-1801-2-52] [PMID: 23476897]
[PMID: 6537799]
[http://dx.doi.org/10.1093/jnci/dji005] [PMID: 15632378]
[http://dx.doi.org/10.1007/s10549-013-2585-z] [PMID: 23760858]
[http://dx.doi.org/10.1038/clpt.2011.372] [PMID: 22617226]
[http://dx.doi.org/10.1016/j.ctrv.2015.01.002] [PMID: 25618289]
[http://dx.doi.org/10.1124/dmd.104.003459] [PMID: 15821042]
[http://dx.doi.org/10.1093/jnci/djg108] [PMID: 14652237]
[http://dx.doi.org/10.1002/cpt.1007] [PMID: 29385237]
[http://dx.doi.org/10.1038/tpj.2014.34] [PMID: 25091503]
[http://dx.doi.org/10.1634/theoncologist.2015-0480] [PMID: 27226358]
[http://dx.doi.org/10.1007/s10549-011-1777-7] [PMID: 21947681]
[http://dx.doi.org/10.1200/JCO.2010.31.4427] [PMID: 21768473]
[http://dx.doi.org/10.1097/FTD.0000000000000195] [PMID: 26192892]
[http://dx.doi.org/10.1016/j.breast.2014.02.008] [PMID: 24685597]
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1470] [PMID: 26847054]
[PMID: 10850424]
[PMID: 25490892]
![Wayfinder Image](/images/wayfinder.jpg)